FY2026 EPS Forecast for Medicus Pharma Lifted by Analyst

Medicus Pharma Ltd (NASDAQ:MDCX) – Research analysts at Brookline Capital Markets increased their FY2026 earnings estimates for shares of Medicus Pharma in a report released on Tuesday, March 31st. Brookline Capital Markets analyst K. Raja now anticipates that the company will post earnings per share of ($0.54) for the year, up from their previous forecast of ($1.25). The consensus estimate for Medicus Pharma’s current full-year earnings is ($1.14) per share. Brookline Capital Markets also issued estimates for Medicus Pharma’s FY2027 earnings at ($0.48) EPS.

Several other equities research analysts have also recently weighed in on MDCX. D. Boral Capital restated a “buy” rating and set a $27.00 target price on shares of Medicus Pharma in a research note on Thursday, March 19th. Weiss Ratings reissued a “sell (d-)” rating on shares of Medicus Pharma in a report on Monday, December 29th. Two investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Medicus Pharma currently has a consensus rating of “Hold” and a consensus price target of $23.50.

Medicus Pharma Price Performance

Shares of NASDAQ:MDCX opened at $0.45 on Thursday. Medicus Pharma has a 1 year low of $0.37 and a 1 year high of $8.94. The stock has a market capitalization of $11.42 million, a price-to-earnings ratio of -0.16 and a beta of 1.16. The company’s 50 day simple moving average is $0.90 and its 200 day simple moving average is $1.67.

Medicus Pharma (NASDAQ:MDCX) last issued its quarterly earnings results on Thursday, March 26th. The company reported ($0.82) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.50).

Hedge Funds Weigh In On Medicus Pharma

A number of institutional investors have recently added to or reduced their stakes in the stock. Jane Street Group LLC bought a new position in Medicus Pharma in the 2nd quarter valued at approximately $41,000. Osaic Holdings Inc. grew its stake in shares of Medicus Pharma by 180.0% during the second quarter. Osaic Holdings Inc. now owns 14,000 shares of the company’s stock worth $42,000 after buying an additional 9,000 shares during the last quarter. Brave Asset Management Inc. acquired a new position in shares of Medicus Pharma during the third quarter worth $46,000. Wilmington Savings Fund Society FSB acquired a new position in shares of Medicus Pharma during the third quarter worth $59,000. Finally, Private Advisor Group LLC lifted its stake in shares of Medicus Pharma by 3.8% in the 3rd quarter. Private Advisor Group LLC now owns 151,500 shares of the company’s stock valued at $351,000 after acquiring an additional 5,500 shares during the last quarter.

Medicus Pharma Company Profile

Medicus Pharma, Inc, traded on the Nasdaq under the ticker MDCX, is a specialty pharmaceutical company focused on the development, acquisition and commercialization of prescription therapies. The company’s core business centers on oncology supportive care and critical care products, with its lead offering being Levoleucovorin injection, an FDA-approved agent designed to reduce toxicity and enhance efficacy of certain chemotherapeutic regimens in colorectal cancer.

Headquartered in the United States, Medicus Pharma has built its portfolio through strategic licensing and acquisition of sterile injectable and oral therapies.